Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings

Treating acute leukaemias of ambiguous lineage

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study

Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup analyses of PALOMA-3

Using AI to examine muscle mass in brain tumour patients